339 related articles for article (PubMed ID: 19754386)
41. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations.
Bevan S; Dichgans M; Wiechmann HE; Gschwendtner A; Meitinger T; Markus HS
Stroke; 2008 Apr; 39(4):1109-14. PubMed ID: 18323512
[TBL] [Abstract][Full Text] [Related]
42. Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases.
Jupp J; Hillier K; Elliott DH; Fine DR; Bateman AC; Johnson PA; Cazaly AM; Penrose JF; Sampson AP
Inflamm Bowel Dis; 2007 May; 13(5):537-46. PubMed ID: 17230539
[TBL] [Abstract][Full Text] [Related]
43. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U
Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of leukotriene biosynthesis.
Ford-Hutchinson AW
Ann N Y Acad Sci; 1991; 629():133-42. PubMed ID: 1952545
[No Abstract] [Full Text] [Related]
45. Leukotrienes and atherosclerosis.
Riccioni G; Bäck M; Capra V
Curr Drug Targets; 2010 Jul; 11(7):882-7. PubMed ID: 20388065
[TBL] [Abstract][Full Text] [Related]
46. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
47. Leukotriene signaling in atherosclerosis and ischemia.
Bäck M
Cardiovasc Drugs Ther; 2009 Feb; 23(1):41-8. PubMed ID: 18949546
[TBL] [Abstract][Full Text] [Related]
48. 5-lipoxygenase: cellular biology and molecular pharmacology.
Werz O
Curr Drug Targets Inflamm Allergy; 2002 Mar; 1(1):23-44. PubMed ID: 14561204
[TBL] [Abstract][Full Text] [Related]
49. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
[TBL] [Abstract][Full Text] [Related]
50. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation.
Wickelgren I
Science; 2004 Feb; 303(5660):941. PubMed ID: 14963296
[No Abstract] [Full Text] [Related]
51. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids.
Rubin P; Mollison KW
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554
[TBL] [Abstract][Full Text] [Related]
52. Designing therapeutically effective 5-lipoxygenase inhibitors.
McMillan RM; Walker ER
Trends Pharmacol Sci; 1992 Aug; 13(8):323-30. PubMed ID: 1413091
[TBL] [Abstract][Full Text] [Related]
53. 15-lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA.
Jeon SG; Moon HG; Kim YS; Choi JP; Shin TS; Hong SW; Tae YM; Kim SH; Zhu Z; Gho YS; Kim YK
Clin Exp Allergy; 2009 Jun; 39(6):908-17. PubMed ID: 19260872
[TBL] [Abstract][Full Text] [Related]
54. 5-Lipoxygenase: enzyme expression and regulation of activity.
Steinhilber D
Pharm Acta Helv; 1994 Jul; 69(1):3-14. PubMed ID: 7938075
[TBL] [Abstract][Full Text] [Related]
55. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
[TBL] [Abstract][Full Text] [Related]
56. Leukotriene receptors as potential therapeutic targets.
Yokomizo T; Nakamura M; Shimizu T
J Clin Invest; 2018 Jul; 128(7):2691-2701. PubMed ID: 29757196
[TBL] [Abstract][Full Text] [Related]
57. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation.
Bäck M; Sultan A; Ovchinnikova O; Hansson GK
Circ Res; 2007 Apr; 100(7):946-9. PubMed ID: 17379835
[TBL] [Abstract][Full Text] [Related]
58. The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo.
Schaible AM; Filosa R; Krauth V; Temml V; Pace S; Garscha U; Liening S; Weinigel C; Rummler S; Schieferdecker S; Nett M; Peduto A; Collarile S; Scuotto M; Roviezzo F; Spaziano G; de Rosa M; Stuppner H; Schuster D; D'Agostino B; Werz O
Biochem Pharmacol; 2016 Jul; 112():60-71. PubMed ID: 27157409
[TBL] [Abstract][Full Text] [Related]
59. Enzymes functional in the syntheses of leukotrienes and related compounds.
Shimizu T
Int J Biochem; 1988; 20(7):661-6. PubMed ID: 2846379
[TBL] [Abstract][Full Text] [Related]
60. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma.
Drazen JM
Pharmacotherapy; 1997; 17(1 Pt 2):22S-30S. PubMed ID: 9017785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
